Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic

about

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic

Item

http://www.wikidata.org/entity/Q58764419

description

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Prevalence of MDM2 amplificati ...... the MD Anderson phase 1 clinic

@en

Prevalence of MDM2 amplificati ...... the MD Anderson phase 1 clinic

@nl

type

Item

label

Prevalence of MDM2 amplificati ...... the MD Anderson phase 1 clinic

@en

Prevalence of MDM2 amplificati ...... the MD Anderson phase 1 clinic

@nl

prefLabel

Prevalence of MDM2 amplificati ...... the MD Anderson phase 1 clinic

@en

Prevalence of MDM2 amplificati ...... the MD Anderson phase 1 clinic

@nl

P1476

Prevalence of MDM2 amplificati ...... the MD Anderson phase 1 clinic

@en

P2093

Daniel D Karp

http://www.w3.org/2001/XMLSchema#string

David S Hong

http://www.w3.org/2001/XMLSchema#string

Kenna Shaw

http://www.w3.org/2001/XMLSchema#string

Kenneth Hess

http://www.w3.org/2001/XMLSchema#string

Neeta Somaiah

http://www.w3.org/2001/XMLSchema#string

Siqing Fu

http://www.w3.org/2001/XMLSchema#string

Vikas Dembla

http://www.w3.org/2001/XMLSchema#string

Vivek Subbiah

http://www.w3.org/2001/XMLSchema#string

P2860

Mdm2 promotes the rapid degradation of p53

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Amplification of a gene encoding a p53-associated protein in human sarcomas

Mutational landscape and significance across 12 major cancer types

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

P304

33232-33243

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.26075

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pedro Coelho Barata

Apostolia Maria Tsimberidou

P577

2018-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30237864

http://www.w3.org/2001/XMLSchema#string

P932

6145698

http://www.w3.org/2001/XMLSchema#string